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Abstract
Purpose of review—For over 60 years, chelation therapy with disodium ethylene diamine
tetraacetic acid (EDTA, edetate) had been used for the treatment of cardiovascular disease (CVD)
despite lack of scientific evidence for efficacy and safety. The Trial to Assess Chelation Therapy
(TACT) was developed and received funding from the National Institutes of Health (NIH) to
ascertain the safety and efficacy of chelation therapy in patients with CVD.
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Recent findings—This pivotal trial demonstrated an improvement in outcomes in
postmyocardial infarction (MI) patients. Interestingly, it also showed a particularly large reduction
in CVD events and all-cause mortality in the prespecified subgroup of patients with diabetes. The
TACT results may support the concept of metal chelation to reduce metal-catalyzed oxidation
reactions that promote the formation of advanced glycation end products, a precursor of diabetic
atherosclerosis.
Summary—In this review, we summarize the epidemiological and basic evidence linking toxic
metal accumulation and diabetes-related CVD, supported by the salutary effects of chelation in
TACT. If the ongoing NIH-funded TACT2, in diabetic post-MI patients, proves positive, this
unique therapy will enter the armamentarium of endocrinologists and cardiologists seeking to
reduce the atherosclerotic risk of their diabetic patients.
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INTRODUCTION
In November 2012, we presented the results of the NIH-funded Trial to Assess Chelation
Therapy (TACT) at the American Heart Association Scientific Sessions in Anaheim,
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California. Metal chelation for atherosclerosis had long been thought to be quackery by
traditional cardiologists, yet persisted in clinical use. In spite of the absence of actionable
data, a safety and efficacy trial of edetate disodium (disodium ethylene diamine tetra acetic
acid, Na2EDTA) chelation in patients following myocardial infarction was funded in 2002
by the NIH, and completed over a decade [1,2].
The results of the primary analysis of TACT were surprising. Instead of debunking a quack
therapy, the results of this double-blind, placebo-controlled clinical trial demonstrated
benefit of 40 intravenous edetate disodium-based chelation infusions in reducing
cardiovascular disease events in a secondary prevention population [1,2] (Fig. 1a). The effect
of metal chelation on diabetic patients with cardiovascular disease (CVD, defined as prior
myocardial infarction) is the focus of this review.
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Of the 1708 post-MI patients studied in TACT, 633 had diabetes [3▪▪]. Diabetic patients
assigned to chelation therapy demonstrated a 41% relative risk reduction in combined
cardiovascular events compared with placebo infusions (P = 0.0002, 5-year number needed
to treat to prevent one event = 6.5) 6.5) (Fig. 1b). There was a 52% relative reduction in the
risk of recurrent myocardial infarction (P = 0.015; Fig. 1c); and a 43% relative risk reduction
in mortality (P = 0.011, 5-year number needed to treat to prevent one death = 12; Fig. 1d)
[3▪▪]. This review will touch upon the key role that essential and toxic metals, may play
upon the development of vascular complications, particularly in patients with diabetes, the
results of a clinical trial of metal chelation, particularly in diabetic patients, and ongoing
research.

BRIEF HISTORY OF CHELATION BEFORE THE TRIAL TO ASSESS
Author Manuscript

CHELATION THERAPY
Chelation, etymologically from chelos, the Greek word meaning claw, refers to the pincer
like manner in which cations are incorporated into an organic molecule referred to as a
chelating agent, forming a complex ring structure. The chelate–chelator complex is usually
more stable, soluble and resistant to dissociation, allowing for effective removal from tissue
and excretion in the urine or in bile [4].
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A nearly ideal chelator, edetate is a synthetic amino acid with high affinity for metallic and
non-metallic cations. EDTA is water soluble and excreted in the urine, forming strong
coordinate bonds with certain ions such as calcium, zinc, cadmium and lead [5]. It was first
developed in Germany in the late 1930s for chelation of calcium stains from textiles, and
later applied to the treatment of heavy metal poisoning and hypercalcemia. The strong bond
of EDTA with calcium led early proponents to hypothesize that it might reduce the calcium
burden of atheromatous plaque [6,7].
In 1956, Clarke et al. [8] described the first use of chelation therapy and showed that 19 out
of 20 patients with severe angina had improvement of symptoms and/or electrocardiographic
findings after edetate disodium chelation infusions. The beneficial effects reported in this
small study were followed by other small case reports and case series that failed to
corroborate the efficacy of chelation in treating atherosclerosis. By the 1970s, chelation

Curr Opin Endocrinol Diabetes Obes. Author manuscript; available in PMC 2018 August 01.

Diaz et al.

Page 3

Author Manuscript

therapy had firmly moved into the realm of complementary and alternative medicine (CAM).
Clinical trials were eventually performed, but were too small individually or in aggregate to
exclude a small-to-moderate beneficial effect [9–13]. Yet over the decades, patients
continued to seek and receive chelation from practitioners. Owing to the unsupported use of
chelation, the NIH released a Request for Applications (RFAs) in 2001 for a safety and
efficacy clinical trial of edetate disodium chelation in cardiovascular disease. The Trial to
Assess Chelation Therapy (TACT) was the result. The positive results in patients with
diabetes suggest that toxic metals may have a role in the excess atherosclerotic risk of such
patients. In order to better understand the TACT results, it is worthwhile; therefore, to
consider the epidemiological and mechanistic links between toxic metals and
atherosclerosis.

TOXIC METALS AND VASCULAR DISEASE MECHANISMS AND EVIDENCE
Author Manuscript

Essential metals are crucial in maintaining cellular homeostasis, but excessive exposure may
lead to metal-induced toxicity by increasing production of reactive oxygen species (ROS).
ROS can overwhelm and deplete the cell’s intrinsic antioxidant defenses leading to oxidative
stress. Iron and copper are the two best-known metals that have the potential of generating
ROS. They are both effectively chelated by the edetates. Other metals, referred to as
xenobiotic or toxic metals, have no role in human physiology and, like lead, may be toxic
even in dilute concentrations. Some of the most commonly found toxic metals in humans
include lead, cadmium, arsenic, and mercury, all of which cause – or at the very least are
associated with – CVD.
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Diabetes-related macrovascular complications, particularly CVD, have been found to be
mediated by advanced glycation end products (AGEs), advanced lipoxygenation end
products (ALEs), and protein oxidation products (PrOPs) [14]. AGEs are heterogeneous
cross-linked complexes formed by the nonenzymatic glycation and oxidation of aldose
sugars with proteins, lipids and nucleic acids [15]. There is also convincing evidence that
formation of chemically active, cross-linked aldose sugars requires metal catalyzed oxygen
chemistry to produce oxygen and hydroxyl radicals. AGEs have a deleterious effect on the
integrity of the vessel walls through several mechanisms, including activation of the receptor
for AGE (RAGE) [16]. RAGE activation triggers rapid generation of ROS and a proinflammatory signaling cascade with expression of pro-atherogenic adhesion molecules [17].
This interaction between AGE and its receptor perpetuates chronic vascular injury, which
may play a role in the progression of diabetic atherosclerosis. These reactions may require
metals that donate or accept electrons, in order to create oxygen and hydroxyl-free radicals.
There is abundant evidence linking toxic metal accumulation and CVD [18–24]. We restrict
our discussion below to lead and cadmium because of their effective chelation by the
edetates.
Lead is a toxic metal found in contaminated water, air, food and soil because of its
nonbiodegradable nature and continuous use. Human exposure to lead occurs mainly
through leaded gasoline still used in piston engine aircraft, lead-containing pipes, smelting
of lead and its combustion, lead-based paints and battery recycling (Fig. 2) [25]. Over the
past three decades, there has been a dramatic drop in mean lead blood levels in the United
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States because of banning lead-based paints and leaded gasoline used by ground vehicles.
However, environmental exposure continues, as evident in the recent public health crisis in
Flint, Michigan because of lead seepage into drinking water. Lead contamination of drinking
water is typically caused by metal corrosion of water pipes, particularly lead service lines.
The incidence of elevated blood lead levels after the city of Flint changed its water source to
the Flint River increased from 2.4 to 4.9% (P < 0.05) [26]. Lead can be inhaled or ingested,
and then absorbed into the bloodstream [27]. Once absorbed, lead moves into the red cell
compartment, where it is bound by metallothionein-like protein, a thiol-containing protein.
Lead has a half-life of about 28–36 days in blood, 1–1.5 months in soft tissue, and about 25–
30 years in bone [28–29]. When lead completes its lifespan in blood, it is released and
displaces calcium in bone. Bone then acts as an endogenous source of lead, releasing lead
back into the bloodstream years after exposure [29]. A single disodium edetate infusion of 3
g will increase lead excretion by nearly 4000% in a few hours [30,31▪].
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Epidemiological data from various National Health and Nutrition Examination Surveys
(NHANES) support an association between toxic metal exposure and CVD events. The
prospective analysis of NHANES III participants showed an increase in all-cause and
cardiovascular mortality, with cause specific deaths highest for myocardial infarction and
stroke at lead blood levels greater than 0.10 μmol/l [32,33]. Several possible mechanisms
have been postulated for the association of lead accumulation and its direct and indirect
effect on CVD. In-vivo and in-vitro studies have shown that one mechanism by which
chronic lead exposure causes CVD is by increasing production of ROS leading to oxidative
stress, limiting nitric oxideavailability and disrupting the nitric oxide signaling cascade [34–
37]. Nitric oxide has important cardioprotective roles including regulation of blood pressure
and vascular homeostasis such as regulation of vascular dilation, local cell growth and
protection of the vessel from injury because of platelet aggregation. Therefore, the impaired
synthesis or excessive oxidative degradation of nitric oxide leads to endothelial dysfunction,
a starting point for atherosclerosis.
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Lead increases protein kinase C (PKC) activity and promotes atherogenicity [38,39]. PKC
regulates many functions including cell growth, vascular smooth muscle contraction, blood
flow and permeability [39]. Lead additionally promotes inflammation, fibrosis and apoptosis
via activation of nuclear factor-κB. Lead also increases the production of endothelin,
vasoconstrictor peptides primarily synthesized and secreted by endothelial cells that can
raise arterial pressure. Khalil-Manesh et al. [40] found that rats exposed to low levels of lead
for 1–12 months had a significant rise in arterial pressure and marked increase in plasma
endothelin 3 concentrations. These and other proposed mechanisms may explain how lead
causes vascular injury in humans. If more than one of these mechanisms is relevant to
human diabetes, then lead may act as a risk factor multiplier, perhaps at least partially
explaining the effect of lead chelation.
Cadmium is another toxic metal that accumulates in the environment and is associated with
atherosclerotic disease. Environmental sources of cadmium include rechargeable batteries,
electronics, building construction, jewelry, toys, plastic production, paint pigments and metal
coating [41–43]. Tobacco leaves, spinach and root vegetables naturally accumulate and
concentrate high levels of cadmium from the soil, dependent on the cadmium content of
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fertilizers. Tobacco use, therefore, is one of the single most important sources of cadmium
exposure [44]. Cadmium accumulates in both the liver and kidneys, protein bound to
metallothionein [45,46]. Because of its slow urinary excretion, cadmium has a half-life up to
38 years [41]. A single disodium edetate infusion of 3 g will increase cadmium excretion by
about 700% in a few hours [30,31▪].
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Similar to lead, there are several mechanisms that have been suggested to explain the role of
cadmium in atherosclerosis. In a systematic review, Tellez-Plaza et al. [47] found evidence
supporting cadmium as a cardiovascular risk factor. Cadmium can indirectly interfere with
antioxidant response by binding to metalloproteins, thereby increasing ROS causing lipid
peroxidation and cellular injury and DNA damage [48]. The Atherosclerosis Risk Factors in
Female Youngsters study examined carotid intima–media thickness in 195 young healthy
women and measured serum metal concentrations, including cadmium. They reported an
independent association between high cadmium levels and intima–media thickness,
exceeding the 90th percentile in distribution, representing early atherosclerotic vessel wall
thickening [49]. Cadmium has also been found to raise blood pressure, an established risk
factor for cardiovascular disease [50,51]. In a large population study of NHANES III
participants between 1988 and 1994, creatinine-corrected urinary cadmium levels in men
were associated with an increase in risk of all-cause and cardiovascular mortality, including
coronary artery disease-associated mortality [52]. Finally, Tellez-Plaza et al. [53▪] examined
3348 American Indian adults ages 45–74 years who participated in the Strong Heart Study
from 1989 to 1991 and measured urine cadmium levels. Urine cadmium levels were
associated with an increased incidence of cardiovascular disease and mortality. The diabetic
subgroup in this study showed a stronger, statistically significant association between
cadmium and cardiovascular disease endpoints when compared with those without diabetes.
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THE TRIAL TO ASSESS CHELATION THERAPY
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Coincident with the interest of the diabetes scientific community in metal-catalyzed oxygen
chemistry as an important part of the formation of AGEs and complications of diabetes, the
cardiology community was in the final phases of planning a metal chelation trial. As noted
above, edetate disodium chelation had been used to treat atherosclerotic complications for
many years. A literature review in 2000 concluded that there was insufficient evidence for or
against the practice [12]. This was followed by a more formal 2002 Cochrane Review again
concluding that there was insufficient evidence to decide on the effectiveness of edetate
sodium to treat atherosclerotic disease [13]. This conclusion sparked the interest of the NIH
to release a RAF for a randomized double-blind, placebo-controlled trial to test the efficacy
and safety of chelation therapy in patients with coronary artery disease. The study that
resulted, TACT, was widely expected to be negative. During the planning phase, high-dose
oral multivitamins and minerals (OMVM) were added in a factorial design, as most
chelation practitioners also recommended that patients take large doses of OMVM during
intravenous chelation [1]. The four randomized groups in the 2 × 2 factorial trial included:
1.

active chelation and active OMVM

2.

active chelation and placebo OMVM
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3.

placebo chelation and active OMVM

4.

placebo chelation and placebo OMVM

Eligible patients had to be at least 50 years of age, have had prior myocardial infarction at
least 6 weeks prior to enrollment, and have a serum creatinine level 2.0 mg/dl or less.
Enrollment took place between 2003 and 2010. There were 1708 patients enrolled in the
clinical trial across 134 sites in the United States and Canada. The blind was broken and
analyses were completed, in 2012.

STUDY TREATMENTS
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Intravenous chelation regimens developed organically through the years, and although the
consistent chelating drug was edetate disodium, other components were often added (Table
1). The TACT infusion regimen included 30 weekly infusions followed by 10 maintenance
infusions, the latter 2 weeks to 2 months apart. By 18 months after randomization, over 90%
of the infusions had been administered. The randomized OMVM or oral placebo was taken
throughout the duration of the trial and consisted of three caplets twice daily, containing 28
individual components (Table 2).

ENDPOINTS AND STATISTICAL POWER
The primary end point was a composite of all-cause mortality, myocardial infarction, stroke,
coronary revascularization and hospitalization for angina. The principal secondary end point
was cardiovascular mortality, recurrent myocardial infarction and stroke.

OVERALL RESULTS
Author Manuscript

The intention-to-treat analyses revealed a statistically significant reduction in the primary
endpoint (hazard ratio 0.82; 95% CI 0.69–0.99; P = 0.035). Although the individual
components of the primary endpoint did not reach statistical significance, all but total
mortality had point estimates favoring active chelation treatments.

TRIAL TO ASSESS CHELATION THERAPY DIABETES SUBGROUP
Patients with diabetes were defined as those who self-reported diabetes, were receiving
pharmacotherapy for diabetes, or had a fasting glucose of at least 126 mg/dl at baseline. Of
the 1708 participants enrolled in the study, 633 (37.1%) patients had diabetes mellitus.

BASELINE CHARACTERISTICS
Author Manuscript

Among the patients with diabetes, 322 were randomized to receive edetate disodium-based
infusions and 311 received placebo infusions. There were no significant between-group
differences in important baseline characteristics. The median age was 65 years, with 19%
women and 11% minorities. The trial encouraged patients to maintain standard, evidencebased treatments for patients with prior MI and diabetes.
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Mean fasting blood sugar was 132 mg/dl, and low-density lipoprotein (LDL) cholesterol was
81 mg/dl. Within the diabetic population, 81% had undergone prior coronary
revascularization (either percutaneous or surgical). There were 92% of patients on aspirin,
clopidogrel or warfarin, and 76% on statins. Treatment of diabetes required insulin in 26%,
and oral hypoglycemics in 61%.

RESULTS OF TRIAL TO ASSESS CHELATION THERAPY IN PATIENTS WITH
DIABETES
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In spite of the arduous nature of the study therapy, 73% of patients completed 30 infusions,
and 61% completed all 40. There was a statistically significant interaction (P of interaction
of the primary endpoint = 0.004) between edetate disodium therapy effect and the presence
of diabetes mellitus at baseline. There was a striking benefit of the edetate disodium
infusions in the diabetic patients randomly assigned to receive active infusions compared
with placebo with 25% vs. 38% incidence of the primary outcome (hazard ratio 0.59; 95%
CI 0.44–0.79; P = 0.0002). There was a 15% absolute decrease in the 5-year Kaplan–Meier
primary event rate. The number of patients that needed to be treated to prevent a single event
over 5 years was 6.5 (Fig. 1b). The prespecified major secondary end point, cardiovascular
death, recurrent myocardial infarction or stroke, was also reduced in those randomized to the
active chelation treatment, with a 40% relative risk reduction (hazard ratio 0.60; 95% CI
0.39–0.91; P = 0.017). Patients with diabetes randomized to EDTA chelation treatment had a
reduction in recurrent MI (hazard ratio 0.60; 0.48; 95% CI 0.26–0.88; P = 0.015) (Fig. 1c),
all-cause mortality (hazard ratio 0.57; 95% CI 0.36–0.88; P = 0.011; Fig. 1d), and coronary
revascularization (hazard ratio 0.68; 95% CI 0.47–0.99; P = 0.042; Table 3). When
compared with diabetic patients, the patients without diabetes did not have this treatment
effect in primary or secondary event outcomes. In patients with diabetes, the Kaplan–Meier
curves continued to separate after infusions were completed, a legacy effect unlike most in
cardiology, and perhaps supporting the beneficial effect of toxic metal removal by EDTA.

DISCUSSION
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In the United States, 23.3 million people have diabetes mellitus [54]. Another 7.2 million are
estimated to have undiagnosed diabetes. Diabetes is a key risk factor for cardiovascular
disease with a two-fold to three-fold increased likelihood of vascular death. The cause of this
excess cardiovascular morbidity and mortality is not completely clear, but the results of
TACT inevitably point to mechanistic speculation. The chelation infusion did not treat
hyperglycemia. In TACT, there were no differences in mean fasting blood glucose levels
from baseline to the 30th infusion in neither the placebo nor the active chelation groups.
There were no differences in pharmacotherapy for diabetes between the treatment groups
throughout the study. This evidence suggests that although hyperglycemia, the hallmark of
diabetes, is a risk factor for cardiovascular disease, it is clearly not the only modifiable risk
factor in diabetic patients.
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CONCLUSION
Edetate disodium chelation, far from standard therapy, is currently a Class 2B indication in
the Stable Ischemic Heart Disease Guidelines [55]. As such, the results of TACT require
replication and mechanistic investigation. With this in mind, NIH (NCCIH, NHLBI,
NIDDK, NIEHS) has funded the second Trial to Assess Chelation Therapy, TACT2. TACT2
will have identical inclusion criteria as TACT, with the exception of including only diabetic
patients post-MI.
TACT2 is currently enrolling with a target sample size of 1200 post-MI diabetic patients. We
welcome potentially interested sites, investigators and patients to contact us for more details,
or log on to www.tact2.org.
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KEY POINTS
•

TACT showed a marked reduction in CVD events and all-cause mortality in
the subgroup of patients with diabetes.

•

The results may support the concept that metal chelation reduces metalcatalyzed oxidation reactions that promote the formation of advanced
glycation end products.

•

TACT2, in diabetic post-MI patients, is currently enrolling patients in an
effort to replicate these findings, and define a mechanism of benefit.
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FIGURE 1.

The Trial to Assess Chelation Therapy Kaplan–Meier estimates of the primary composite
endpoint: edetate disodium (EDTA) chelation therapy versus placebo (a), primary composite
end point: edetate disodium chelation therapy versus placebo, subset of patients with
diabetes mellitus (b), myocardial infarction in patients with diabetes mellitus by infusion
group (c), mortality in patient with diabetes mellitus by infusion group (d). CI, confidence
interval; TACT, Trial to Assess Chelation Therapy.
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FIGURE 2.
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Central illustration. Heavy metals as a risk factor for atherosclerotic cardiovascular disease
and the benefits of chelation therapy. Major sources and routes of exposure, mechanisms at
the molecular and cellular level, responses at the tissue and organ level, and subclinical and
clinical cardiovascular effects on the basis of experimental and epidemiological evidence are
shown for lead and cadmium. Arrows denote direction of flow. Na2EDTA, disodium
ethylene diamine tetra acid; NO, nitric oxide; TACT, Trial to Assess Chelation Therapy.
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The Trial to Assess Chelation Therapy chelation components
Up to 3 g of disodium EDTAa
2 g of magnesium chloride
100 mg of procaine HCl
2500 U of heparin
7 g of ascorbate
2 mEq KCl
840 mg sodium bicarbonate
250 mg pantothenic acid
100 mg of thiamine
100 mg of pyridoxine
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Add with sterile water to 500 ml

a

The maximum dose of EDTA was 3 g for patients who have at least 60 kg of lean body weight and normal kidney function. Reduction in kidney
function and/or lower lean body weight led to a reduction in the total EDTA dose infused.
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High-dose oral contents used in TACT
High-dose regimen (taken twice daily)

Total amount for 6 pills

% RDA

Vitamin A

25 000 IU

500%

Vitamin C

1200 mg

2000%

Vitamin D3

100 IU

25%

Vitamin E

400 IU

1333%

60 μg

75%

Thiamin

100 mg

6667%

Niacin

200 mg

1000%

Vitamin B6

50 mg

2500%

Folate

800 μg

200%

Vitamin B12

100 μg

1667%

Biotin

300 μg

100%

Pantothenic acid

400 mg

4000%

Calcium

500 mg

50%

Iodine

150 μg

100%

Magnesium

500 mg

125%

Zinc

20 mg

133%

Selenium

200 μg

286%

Vitamin K1
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Copper
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2 mg

100%

Manganese

20 mg

400%

Chromium

200 μg

167%

Molybdenum

150 μg

200%

Potassium

99 mg

3%

Choline

150 mg

a

Inositol

50 mg

a

PABA (para-aminobenzoic acid)

50 mg

a

Boron

2 mg

a

Vanadium

39 μg

a

100 mg

a

Citrus bioflavanoids
RDA, recommended daily allowance.

a

Recommended daily allowance not established. Other ingredients: croscarmellose sodium, microcrystalline cellulose, magnesium stearate,
hydroxypropyl cellulose, and silicon dioxide.
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Clinical end points by infusion arms for patients with diabetes mellitus in TACT
EDTA chelation (n = 322)

Placebo (n = 311)

Hazard ratio (95% CI)

P value

Primary end point

80 (25%)

117 (38%)

0.59 (0.44–0.79)

< 0.001

Death

32 (10%)

50 (16%)

0.57 (0.36–0.88)

0.011

Ml

16 (5o/o)

30 (10%)

0.48 (0.26–0.88)

0.015

Stroke

4 (1o/o)

3 (1%)

1.19 (0.27–5.30)

0.829

Coronary

48 (15%)

62 (20%)

0.68 (0.48–0.99)

0.042

5 (2%)

6 (2%)

0.72 (0.22–2.36)

0.588

Secondary end point

35 (11%)

52 (17%)

0.60 (0.39–0.91)

0.017

Cardiovascular death

19 (6%)

27 (9%)

0.63 (0.35–1.13)

0.118

End point

Revascularization
Hospitalization for angina
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CI, confidence interval; MI, myocardial infarction.
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